{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:05:35Z","timestamp":1791291935729,"version":"4.1.0"},"reference-count":58,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Fresenius Kabi USA, LLC"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.2217\/fon-2023-0026","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T08:24:44Z","timestamp":1692779084000},"page":"145-158","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Achieving White Blood Cell Equity: Are the Safety Profiles of Biosimilar and Reference Pegfilgrastims Comparable?"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3655-9602","authenticated-orcid":false,"given":"Arturo","family":"Loaiza-Bonilla","sequence":"first","affiliation":[{"name":"Capital Health Cancer Center, Hopewell, NJ 08534, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray D","family":"Page","sequence":"additional","affiliation":[{"name":"The Center for Cancer & Blood Disorders, Fort Worth, TX 76104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0127-4"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.2741\/2095"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2016.10.008"},{"key":"e_1_3_7_6_1","unstructured":"US Food and Drug Administration . Highlights of Prescribing Information Neulasta\u00ae (Pegfilgrastim) (2015). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125031s180lbl.pdf"},{"key":"e_1_3_7_7_1","unstructured":"US Food and Drug Administration . Orphan Drug Designations and Approvals (2013). https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=413013"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg019"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf130"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.3.727"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.3816\/SCT.2005.n.016"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.102"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-12-1416"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2597-1"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2013.09.015"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"e_1_3_7_17_1","volume-title":"Biologics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023\u20132028)","author":"Research and Markets","year":"2023","unstructured":"Research and Markets . Biologics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023\u20132028) (2023). https:\/\/www.researchandmarkets.com\/reports\/4828093\/biologics-market-growth-trends-covid-19"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S164201"},{"key":"e_1_3_7_19_1","unstructured":"US Food and Drug Administration . Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance For Industry (2015). https:\/\/www.fda.gov\/media\/82647\/download"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00422-1"},{"key":"e_1_3_7_21_1","unstructured":"US Food and Drug Administration . Highlights of Prescribing Information FULPHILA\u2122 (Pegfilgrastim-jmdb) (2018). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761075s000lbl.pdf"},{"key":"e_1_3_7_22_1","unstructured":"US Food and Drug Administration . Highlights of Prescribing Information Udenyca\u2122 (Pegfilgrastim-cbqv) (2018). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761039s000lbl.pdf"},{"key":"e_1_3_7_23_1","unstructured":"US Food and Drug Administration . Highlights of Prescribing Information Ziextenzo\u2122 (Pegfilgrastim-bmez) (2019). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761045lbl.pdf"},{"key":"e_1_3_7_24_1","unstructured":"US Food and Drug Administration . Highlights of Prescribing Information Nyvepria\u2122 (Pegfilgrastim-apgf) (2020). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761111lbl.pdf"},{"key":"e_1_3_7_25_1","unstructured":"US Food and Drug Administration . Highlights of Prescribing Information Fylnetra\u00ae (Pegfilgrastim-pbbk) (2022). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761084s000lbl.pdf"},{"key":"e_1_3_7_26_1","unstructured":"US Food and Drug Administration . Highlights of Prescribing Stimufend\u00ae (Pegfilgrastim-fpgk) (2022). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761173s000lbl.pdf"},{"key":"e_1_3_7_27_1","unstructured":"Generics and Biosimilars Initiative . Biosimilars of Pegfilgrastim (2014). https:\/\/gabionline.net\/biosimilars\/general\/Biosimilars-of-pegfilgrastim"},{"key":"e_1_3_7_28_1","unstructured":"Adis Insight . Drug Profile. Pegfilgrastim Biosimilar \u2013 Lupin (2022). https:\/\/adisinsight.springer.com\/drugs\/800040515#:\u223c:text=Pegfilgrastim"},{"key":"e_1_3_7_29_1","unstructured":"Lupin . Lupin Announces U.S. FDA Acceptance for Pegfilgrastim Biosimilar Application (2021). https:\/\/www.lupin.com\/lupin-announces-u-s-fda-acceptance-for-pegfilgrastim-biosimilar-application\/"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3620-x"},{"key":"e_1_3_7_31_1","unstructured":"Mylan . Mylan and Viatris (2022). https:\/\/www.mylan.com\/"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01459-y"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.269"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00987-3"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.05.020"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.578"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01387-x"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2643-3"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13731"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14226"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-018-0114-9"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03639-5"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2016-0016"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0011"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006288731"},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91475-4"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2013-0145"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008320318"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1159\/000478077"},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00356-3"},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.10.034"},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom9090410"},{"issue":"2","key":"e_1_3_7_53_1","first-page":"28","article-title":"Biosimilars stimulate quality and innovation","volume":"6","author":"van Corven E","year":"2018","unstructured":"van Corven E . Biosimilars stimulate quality and innovation. Pharm. Bioprocess. 6(2), 28\u201329 (2018).","journal-title":"Pharm. Bioprocess."},{"key":"e_1_3_7_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa297"},{"key":"e_1_3_7_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41203"},{"key":"e_1_3_7_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.11.009"},{"key":"e_1_3_7_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211041961"},{"key":"e_1_3_7_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa502"},{"key":"e_1_3_7_59_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-020-03190-z"},{"key":"e_1_3_7_60_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024537"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-0026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:48Z","timestamp":1719125088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-0026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.2217\/fon-2023-0026"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-0026","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-01-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}